Medable Announces New Study Results from Tufts CSDD Analysis on Financial Benefits of DCTs

Article

Medable Inc. today announced results from a Tufts CSDD analysis which shows that, on average, decentralized clinical trials (DCTs) are associated with reduced clinical trial timelines and can achieve net financial benefits ranging from five to 14 times for Phase II and Phase III trials, respectively. The findings are based on financial modeling and analysis of trial data from the Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine, and more than 150 clinical trials enabled by Medable software.

The full report can be accessed here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
Related Content
© 2024 MJH Life Sciences

All rights reserved.